Washington,
D.C. 20549
FORM
6-K
REPORT
OF
FOREIGN ISSUER
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For
the month of October 2005
Commission
File Number 000-51122
pSivida
Limited
(Translation
of registrant’s name into English)
Level
12
BGC Centre
28
The
Esplanade
Perth
WA
6000
(Address
of principal executive offices)
(Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F).
Form
20-F
ý Form
40-F o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7):
Indicate
by check mark whether the registrant by furnishing the information contained
in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
o No
ý
If
"Yes"
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82- ___.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant,
pSivida Limited, has duly caused this report to be signed on its behalf by
the
undersigned, thereunto duly authorized.
| Date: October 26, 2005 | ||
| pSivida Limited | ||
| |
|
|
| By: | /s/ Aaron Finlay | |
|
|
||
| Aaron
Finlay Chief Financial Officer and Company Secretary |
||
EXHIBIT
INDEX
|
EXHIBIT
99.1:
|
pSivida
to ring closing on NASDAQ Stock
Market
|
-
2
-
|
ASX/MEDIA
RELEASE
|
 |
26
October 2005
pSivida
to ring closing on NASDAQ Stock Market
Company
celebrates nine months on The NASDAQ
Global
bio-nanotech company pSivida Limited (ASX:PSD,
NASDAQ:PSDV, Xetra:PSI)
is
pleased to announce that CEO, Mr Gavin Rezos will preside over the NASDAQ
closing bell ceremony today at the Times Square NASDAQ Market site in New
York
city. The event will take place on Wednesday, 26 October 2005 at 4:00pm EDT
US
(Thursday, October 27 at 4:00am WST Australia).
pSivida
listed on a Level 2 American Depositary Receipt (ADR) programme on the NASDAQ
National Market in January 2005 in which Citigroup was selected as the
Depositary Bank to administer the ADR programme. The number of ADR’s on issue
has more than quadrupled over this period reflecting the greater visibility
the
Company has achieved in the United States, the world’s largest healthcare and
investment markets.
In
one of
the first large transactions in the medical nanotech industry, pSivida recently
announced that it had entered into a US$104 million definitive merger agreement
to acquire Control Delivery Systems (CDS). CDS is a privately owned US based
drug delivery company with the potential to create a global bio-nanotech
company
specializing in drug delivery, with revenues from existing products and
generating long-term value through its diversified late-stage product portfolio.
“We
are
honored to be ringing the closing bell today at NASDAQ,” said Mr Rezos. “Our
NASDAQ listing, completion of recent successful capital raisings and the
planned
acquisition of CDS mark the beginning of a strong growth in business development
for our company in the US.”
To
view
pSivida’s closing ceremony live, please visit the NASDAQ web cam link at
http://www.nasdaq.com/reference/marketsite_about.stm.
Viewers
are advised to visit the NASDAQ web cam site twenty minutes prior to screening
and download the webcam in order to have time to troubleshoot technical
difficulties.
-ENDS-
Released
by:
|
pSivida
Limited
Brian
Leedman
Investor
Relations
pSivida
Limited
Tel:
+ 61 8 9226 5099
brianl@psivida.com
|
US
Public Relations
Beverly
Jedynak
President
Martin
E. Janis & Company, Inc
Tel:
+1 (312) 943 1100 ext. 12
bjedynak@janispr.com
|
UK
& Europe Public Relations
Mark
Swallow / Helena Podd
Citigate
Dewe Rogerson
Tel:
+44 (0)20 7638 9571
mark.swallow@citigatedr.co.uk
|
NOTES
TO EDITORS:
pSivida
Limited
pSivida
is a global bio-nanotech company committed to the biomedical sector and the
development of products in healthcare. The company’s focus is the development
and commercialisation of a modified form of silicon (porosified or
nano-structured silicon) known as BioSilicon™.
pSivida
owns the intellectual property pertaining to BioSilicon™ for use in or on humans
and animals. The IP portfolio consists of 29 patent families, 34 granted
patents
and over 80 patent applications. The core patent, which recognises BioSilicon™
as a biomaterial was granted in the UK in 2000 and in the US in 2001.
pSivida
is listed on NASDAQ (PSDV),
the
Australian Stock Exchange (PSD)
and in
Germany on the Frankfurt Stock Exchange on the XETRA system (German Symbol:
PSI. Securities Code (WKN) 358705).
pSivida’s shares also trade in the United Kingdom on the OFEX International
Market Service (IMS) under the ticker symbol PSD.
pSivida
is a founding member of the NASDAQ Health Care Index and the Merrill Lynch
Nanotechnology Index.
The
Company’s strategic partner and largest shareholder is the QinetiQ group, the
largest science and technology company in Europe. QinetiQ is the former UK
government Defence Evaluation Research Agency and was instrumental in
discovering BioSilicon™. pSivida enjoys a strong relationship with QinetiQ
having access to its cutting edge research and development facilities. For
more
information on QinetiQ visit www.qinetiq.com.
For
more
information visit www.psivida.com
This
announcement does not constitute an offer of any securities for sale or the
solicitation of an offer to buy any securities. Any securities offered may
not
be or have not been registered under the US Securities Act of 1933, as amended,
and may not be offered or sold in the United States absent registration or
an
applicable exemption from registration requirements."
This
document contains forward-looking statements that involve risks and
uncertainties. Although we believe that the expectations reflected in such
forward-looking statements are reasonable at this time, we can give no assurance
that such expectations will prove to be correct. Given these uncertainties,
readers are cautioned not to place undue reliance on such forward-looking
statements. Actual results could differ materially from those anticipated
in
these forward-looking statements due to many important factors including:
our
failure to develop applications for BioSiliconTM
due to
regulatory, scientific or other issues, our inability to negotiate and
consummate the proposed acquisition, our inability to successfully integrate
the
CDS’s operations and employees; the failure of the CDS’s products
to
achieve expected revenues and the combined entity’s inability to develop
existing or proposed products. Other reasons are contained in cautionary
statements in the Registration Statement on Form 20-F filed with the U.S.
Securities and Exchange Commission, including, without limitation, under
Item
3.D, "Risk Factors" therein. We do not undertake to update any oral or written
forward-looking statements that may be made by or on behalf of
pSivida.